Anti-Met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products
Use of a monoclonal antibody directed against the extracellular domain of hepatocyte growth factor is disclosed for the preparation of a medicament for the treatment of tumors and/or metastases and of a diagnostic tool for detecting neoplastic cells as well as vectors comprising at least a portion of the nucleotide sequence encoding the anti-Met monoclonal antibody, products containing the anti-Met monoclonal antibody and/or at least one fragment thereof and at least one kinase inhibitor.
1. A method of treating a tumor or tumor metastases that express MET comprising administering to a patient in need thereof a lentiviral vector containing a nucleotide sequence encoding
i) the anti-Met monoclonal antibody AntiMET-R,
ii) a fragment containing the epitope binding region of the anti-Met monoclonal antibody AntiMET-R, or
iii) a genetically engineered or humanized antibody containing the complementarity determining regions (CDRs) of the anti-Met monoclonal antibody AntiMET-R, wherein CDR-H1 is SEQ ID NO.:8, CDR-H2 is SEQ ID NO.:9, CDR-H3 is SEQ ID NO.:10, CDR-L1 is SEQ ID NO.:11, CDR-L2 is SEQ ID NO.:12 and CDR-L3 is SEQ ID NO.:13
in an amount sufficient to effect said treatment,
wherein said nucleotide sequence is expressed so as to cause shedding of the extracellular portion of HGFR and HGFR down regulation in said tumor or tumor metastasis cells and thereby inducing an anti-tumor or anti-metastatic effect,
wherein said vector is administered in form of a particle by intra-tumor infusion and
wherein said anti-Met monoclonal antibody AntiMET-R is produced by the hybridoma cell line ICLC PD 05006.
2. The method according to claim 1 , wherein said nucleotide sequence comprises:
i) SEQ ID NO.:1 and SEQ ID NO.:2, or
ii) a nucleotide sequence corresponding to SEQ ID NO.:1 and SEQ ID NO.:2, wherein one or more silent substitutions are present.
3. The method according to claim 1 wherein said method further comprises administering to said patient at least one kinase inhibitor.
4. The method according to claim 3 wherein said at least one kinase inhibitor is selected from the group consisting of K252A staurosporin analogue; (3Z)-5-[(2,6-dichlorobenzyl)sulfonyl]-3-[(3,5-dimethyl-4-{[(2R)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]carbonyl}-1H-pyrrol-2-yl)methylene]-1,3-dihydro-2H-indol-2-one; [(3Z)—N-(3-chlorophenyl)-3-({3,5-dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl}methylene)-N-methyl-2-oxoindoline-5-sulfonamide]; [(3Z)-5-(2,3-dihydro-1H-indol-1-ylsulfonyl)-3-({3,5-dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl}methylene)-1,3-dihydro-2H-indol-2-one]; and [(3Z)—N-(3-chlorophenyl)-3-{[3,5-dimethyl-4-(3-morpholin-4-ylpropyl)-1H-pyrrol-2-yl]methylene}-N-methyl-2-oxoindoline-5-sulfonamide].
5. The method according to claim 4 wherein said at least one kinase inhibitor is administered separately from said nucleotide sequence.
6. The method according to claim 4 wherein said at least one kinase inhibitor is administered simultaneously with said nucleotide sequence.
7. The method according to claim 4 wherein said at least one kinase inhibitor and said nucleotide sequence, are administered sequentially.